Opko Health Finalizes Purchase of NK-1 Compounds from Schering
OPK | Quote | Chart | News | PowerRating -- Opko Health, Inc. has announced that it has completed the acquisition of rolapitant and a related compound from Schering Corp., a subsidiary of Merck & Co., Inc.
Rolapitant, a neurokinin-1 (NK-1) receptor antagonist, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications, the Company noted in a release. Phase I clinical testing has also been initiated for a second compound in the same class. It is anticipated that these compounds may have advantages over presently marketed products.
"We are pleased to complete the acquisition of these valuable assets from Schering, and we look forward to rapidly completing development of rolapitant, the most advanced project among the assets acquired," said Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer.
Opko said that NK-1 receptors are highly concentrated in the brain and are also found in other tissues of the body. Activation of NK-1 receptors leads to the release of neurotransmitters and other signaling molecules that play a central role in controlling nausea and vomiting and other basic functions.
Opko is a specialty healthcare company involved in the discovery, development, and commercialization of proprietary pharmaceutical products, medical devices, vaccines, diagnostic technologies and imaging systems.
((Comments on this story may be sent to health@closeupmedia.com))
For full details on Merck & Co (MRK) MRK. Merck & Co (MRK) has Short Term PowerRatings at TradingMarkets. Details on Merck & Co (MRK) Short Term PowerRatings is available at This Link.
For full details on Opko Health Inc. (OPK) OPK. Opko Health Inc. (OPK) has Short Term PowerRatings at TradingMarkets. Details on Opko Health Inc. (OPK) Short Term PowerRatings is available at This Link.
- AnaptysBio announces collaboration with Merck - 02/09/10
- Critical Alerts for Merck, Lowe's, MEMC Electronic Materials, Lennar, and Kinross Gold Released by Seven Summits Research - 02/09/10
- Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results - 02/09/10
- Emerging Combination Agent from Merck Will Garner Peak Year Sales of More Than $250 Million for the Treatment of Asthma - 02/08/10
- AnaptysBio Announces Strategic Collaboration with Merck & Co., Inc. - 02/08/10
- More News >>
